Frost & Sullivan’s latest Growth Opportunities in the US Telehealth Market, Forecast to 2021 selected Tactio’s app-enabled telehealth solution, TactioRPM, as one of its top participants. The research offers an in-depth view of the US telehealth market broken down into 18 market segments, three of them referencing Tactio as a "notable participant": Mobile Health (mHealth); Remote Patient Monitoring (RPM): and TelePharmacy
Four major market segments- RPM, virtual telehealth visits, mHealth, and personal emergency response systems (PERS)-are said to have exemplified the progress that telehealth services and systems have made in remote management of post-acute care patients or among patients with chronic conditions. This analysis finds the overall US telehealth market will increase by a compound annual growth rate (CAGR) of 29.3% from 2016 to 2021. Frost & Sullivan also predicts that within 5 to 7 years, telehealth will become a mainstream health option. Meanwhile, the global proliferation of the Internet of Medical Things (IoMT) will reduce the number of new chronic condition patients.
Tactio, headquartered in Montreal, Canada, services payers, providers and pharma through a global network of channel partners in North America, Europe and South America. The company will demonstrate its TactioRPM platform at ATA 2017 in Orlando this week, and Hospitalar in Sao Paulo, Brazil, May 16-19.
Frost & Sullivan’s analysis can be viewed here.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Cell and Gene Therapy Check-in 2024
January 18th 2024Fran Gregory, VP of Emerging Therapies, Cardinal Health discusses her career, how both CAR-T therapies and personalization have been gaining momentum and what kind of progress we expect to see from them, some of the biggest hurdles facing their section of the industry, the importance of patient advocacy and so much more.
Tirzepatide Demonstrates Significant Benefits for Patients with Pre-Diabetes, Obesity Over 176 Weeks
November 14th 2024Results from the Phase III SURMOUNT-1 study show that tirzepatide, a dual GIP and GLP-1 receptor agonist, achieved substantial average weight loss of 22.9% in patients with pre-diabetes and obesity.